Quantcast
Last updated on April 17, 2014 at 10:25 EDT

VIVUS to Present at the 2011 JP Morgan Healthcare Conference

January 5, 2011

MOUNTAIN VIEW, Calif., Jan. 5, 2011 /PRNewswire/ — VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 29th Annual JP Morgan Healthcare Conference.

The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Wednesday, January 12, 2011 at 8:30 a.m. PT. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com


    CONTACT:
    --------

                              Investor
    VIVUS, Inc.               Relations:       The Trout Group
    Timothy E. Morris                          Brian Korb
    Chief Financial Officer                    bkorb@troutgroup.com
    650-934-5200                               646-378-2923

SOURCE VIVUS, Inc.


Source: newswire